Business
Soligenix Receives US Patent for Dusquetide Related Analogs
PRINCETON, N.J., April 4, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on
About this update from Soligenix, Inc.
[{"type":"text","content":" PRINCETON, N.J., April 4, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the US Patent Office will issue the patent titled \"Novel Peptides for Treating and Preventing Immune-Related Disorders, Including Treating and Preventing Infection by Modulating Innate Immunity\" on April 9, 2019. The new patent (#10,253,068) claims composition of matter for novel innate defense regulator (IDR) analogs, expanding patent protection to more diverse analog structures. Therapeutic use claims in oral mucositis, colitis, and infectious disease, both alone and in conjunction with antibiotics, will also issue. \nDusquetide (the active ingredient in SGX942) is a novel, first-in-class IDR. It modulates the response of the innate immune system in response to various stimuli, including infection, tissue damage and inflammation. Dusquetide has demonstrated efficacy in an extensive array of preclinical models emphasizing all three aspects of its activity. SGX942 demonstrated positive results in a Phase 2 study in the treatment of oral mucositis in head and neck cancer (HNC) patients. SGX942 at a dose of 1.5 mg/kg successfully reduced the median duration of severe oral mucositis by 67% in patients receiving the most aggressive chemoradiation therapy for treatment of their cancer. In addition to the oral mucositis findings, an increased incidence of \"complete response\" of tumor at the one month and 12-month follow-up visits were observed. Decreases in infection rate and an increase in the 12-month survival rate were also observed with SGX942 treatment. \nSGX942 is currently being evaluated in a pivotal, Phase 3, randomized, double-blind, placebo-controlled, multinational clinical study for the treatment of oral mucositis in HNC patients. The ongoing Phase 3 trial, referred to as the \"DOM–INNATE\" study (Dusquetide treatment in Oral Mucositis – by modulating INNATE immunity), is actively enrolling patients in the US and Europe.\n\"Soligenix continues to pursue broad patent coverage for dusquetide and its library of related IDR analogs, first with composition of matter claims followed by therapeutic use claims, such as in oral mucositis,\" stated Chris...